Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off.

ABSTRACT:

Objective

To compare the efficacy and safety of direct switch from levodopa/benserazide (LB) to levodopa/carbidopa/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson's disease (PD) experiencing wearing off (WO).

Methods

In this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.

Results

Seventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. B

SUBMITTER: Yu C 

PROVIDER: S-EPMC12672222 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature